Logo del repository
  1. Home
 
Opzioni

Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

Magbanua M. J. M.
•
Hendrix L. H.
•
Hyslop T.
altro
Rugo H. S.
2021
  • journal article

Periodico
JOURNAL OF THE NATIONAL CANCER INSTITUTE
Abstract
Background: We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy. Methods: Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS. Results: Latent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9%), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P <. 001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model. Conclusions: We identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.
DOI
10.1093/jnci/djaa113
WOS
WOS:000648946500015
Archivio
http://hdl.handle.net/11368/3019309
info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85098011041
https://academic.oup.com/jnci/article/113/4/443/5889954
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023821/
Diritti
closed access
license:copyright editore
license:copyright editore
license:digital rights management non definito
license uri:iris.pri00
FVG url
https://arts.units.it/request-item?handle=11368/3019309
Soggetti
  • Breast Neoplasm

  • Female

  • Human

  • Neoplastic Cells, Cir...

  • Prognosi

  • Progression-Free Surv...

  • Proportional Hazards ...

  • Reproducibility of Re...

  • Retrospective Studie

  • Treatment Outcome

google-scholar
Get Involved!
  • Source Code
  • Documentation
  • Slack Channel
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your nstitution's web identity.

Need professional help?

The original creators of DSpace-CRIS at 4Science can take your project to the next level, get in touch!

Realizzato con Software DSpace-CRIS - Estensione mantenuta e ottimizzata da 4Science

  • Impostazioni dei cookie
  • Informativa sulla privacy
  • Accordo con l'utente finale
  • Invia il tuo Feedback